期刊文献+

高效液相色谱法测定缬沙坦氨氯地平片中的有关物质 被引量:7

Determination of related substances in valsartan and amlodipine tablets by HPLC
原文传递
导出
摘要 目的:建立测定缬沙坦氨氯地平片中有关物质的HPLC法。方法:采用KromasilC18(250mm×4.6mm,5μm)色谱柱,流动相为20mmol·L-1庚烷磺酸钠溶液(含0.7%三乙胺,用磷酸调pH值至3.0)(A)-乙腈(B),梯度洗脱;柱温35℃;流速1.0mL·min-1;进样量20μL;检测波长237nm。结果:缬沙坦、氨氯地平和各有关物质的分离符合要求,缬沙坦的已知杂质B、杂质C和氨氯地平的已知杂质D的线性范围及相关系数分别为:0.161~16.103μg·mL-1(n=9,r=1.0000),0.080-8.019μg·mL-1(n=9,r=1.0000),0.063~2.110μg·mL-1(n=9,r=0.9998);检测限分别为0.41,0.72,0.88ng;定量限分别为1.36,2.41,2.94ng;回收率分别为99.8%(n=9,RSD为3.59%),98.6%(n=9,RSD为1.02%),108.5%(n=9,RSD=3.61%)。结论:缬沙坦氨氯地平片中主成分与已知杂质及其他有关物质均分离良好,该方法简单、准确、可靠、专属性强,可用于缬沙坦氨氯地平片有关物质的考察。 Objective : To establish an HPLC method for the determination of the relative substances in val- sartan and amlodipine tablets. Methods: The separation was carried out on a Kromasil C18 column (250 mm ×4.6 mm, 5μm) with gradient elution. The mobile phase consisted of 20 retool. L-1 sodium heptanesulfonate solution, in which 7.0 mL of triethylamine was added into 1 000 mL of water, and pH was adjusted to 3.0 with phosphoric acid (A)-acetonitrile (B). The program was follows: 0 - 10 min, 37% B; 10 - 30 min, 37% B→70% B; 30 45 min, 70% B; 45 -50 min, 70% B→37% B; 50 -60 rain, 37% B. Column temperature was set at 35 ℃. The flow rate was at 1.0 mL. min-1 and the injection volume was 20 μL. The detection wavelength was set at 237 nm. Results: The separation of valsartan, amlodipine and the relative substances met the requirements. The linear ran- ges of the related substances B and C of valsartan, and the related substance D of amlodipine were 0. 161 - 16. 103 μg-mL-1(n=9, r=1.000), 0. 080 - 8. 019 μg.mL-1(n =9, r =1.000) 0.063 -2. 11 μg.mL-1(n =9,r = 0.9998). The LODs were0.41, 0.72 and0.88 ng, and LOQs were 1.36, 2.41 and 2.94ng, respectively. The recoveries were 99.8% (n=9, RSD=3.59%), 98.6% (n=9, RSD=1.02%) and 108.5% (n=9, RSD = 3.61% ). Conclusion: The related substances B and C of valsartan and D of amlodipine or other unknown impuri- ties can be well separated from main ingredients of valsartan and amlodipine. The method is simple, accurate, reli- able and specific. It can be used to determinate the related substances of valsartan and amlodipine tablets.
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第19期2323-2327,2331,共6页 Chinese Journal of New Drugs
关键词 高效液相色谱法 缬沙坦氨氯地平片 有关物质 HPLC valsartan and amlodipine tablets related substances
  • 相关文献

参考文献6

二级参考文献62

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2芦璐,宗俊学,高阳.血栓形成标志物与原发性高血压的关系[J].中华老年心脑血管病杂志,2005,7(4):230-232. 被引量:10
  • 3吕雄胜,吴绍长,徐梅玉.缬沙坦联合氨氯地平对老年性高血压左心室构型的影响[J].心脑血管病防治,2005,5(6):32-34. 被引量:4
  • 4NEAL B, MACMAHON S, CHAPMAN N, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration [ J ], Lancet, 2000,356 ( 9246 ) : 1955 - 1964.
  • 5CHOBANIAN AV, BAKRISGL, BLACKHR, etal. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure [ J ]. Hypertension, 2003,42(6) :1206 - 1252.
  • 6The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology ( ESC). 2007 guidelines for the management of arterial hypertension [ J ]. J Hypertension, 2007, 25 (6) : 1105 -1187.
  • 7BENETOS A, THOMAS F, BEAN KE, et al. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population [ J]. J Hypertension, 2003, 21 (9) :1635 - 1640.
  • 8WEBER MA, JULIUS S, KJELDSEN SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial [ J]. Lancet, 2004,363 ( 9426 ) :2049 - 2051.
  • 9PEPINE CJ, KOWEY PR, KUPFER S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease [ J ]. J Am Coll Cardiol, 2006, 47 (3) :547 - 551.
  • 10The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)[J]. JAMA, 2002, 288(23) :2981 -2997.

共引文献15

同被引文献49

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部